Ultragenyx Pharmaceutical (RARE) Other Operating Expenses (2017 - 2026)
Ultragenyx Pharmaceutical (RARE) posted quarterly Other Operating Expenses of $30.0 million for Q1 2026, up 3.45% year-over-year from $29.0 million in Q1 2025, and up 2.23% quarter-over-quarter from $29.3 million in Q4 2025.
Ultragenyx Pharmaceutical (RARE) Other Operating Expenses (2017 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Other Operating Expenses for 10 consecutive years, with $30.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Operating Expenses rose 3.45% year-over-year to $30.0 million; the TTM figure through Mar 2026 stood at $110.3 million (up 24.72% YoY), while the FY2025 annual figure was $109.0 million, up 41.56% from the prior year.
- Other Operating Expenses climbed to $30.0 million in Q1 2026 per RARE's latest filing, from $29.3 million in the prior quarter.
- Across five years, Other Operating Expenses topped out at $30.0 million in Q1 2026 and bottomed at $5.3 million in Q4 2022.
- Historically, Other Operating Expenses has averaged $17.0 million across 5 years, with a median of $17.2 million in 2024.
- Annual changes were most pronounced in 2022 — Other Operating Expenses soared 163.71% — and 2026, when it advanced 3.45%.
- Ultragenyx Pharmaceutical's Other Operating Expenses stood at $5.3 million in 2022, then jumped by 122.64% to $11.8 million in 2023, then soared by 44.96% to $17.2 million in 2024, then soared by 70.95% to $29.3 million in 2025, then increased by 2.23% to $30.0 million in 2026.
- Business Quant data shows RARE's Other Operating Expenses at $30.0 million in Q1 2026, $29.3 million in Q4 2025, and $28.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.61 Bn | 2.33 Bn | 180.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 34.00 Mn |
| Mar 31, 2026 | 30.00 Mn |
| Dec 31, 2025 | 29.35 Mn |
| Sep 30, 2025 | 27.99 Mn |
| Jun 30, 2025 | 23.00 Mn |
| Mar 31, 2025 | 29.00 Mn |
| Dec 31, 2024 | 17.17 Mn |
| Sep 30, 2024 | 21.02 Mn |
| Jun 30, 2024 | 21.28 Mn |
| Mar 31, 2024 | 17.53 Mn |
| Dec 31, 2023 | 11.84 Mn |
| Sep 30, 2023 | 10.99 Mn |
| Jun 30, 2023 | 9.91 Mn |
| Mar 31, 2023 | 12.26 Mn |
| Dec 31, 2022 | 5.32 Mn |
| Sep 30, 2022 | 8.63 Mn |
| Jun 30, 2022 | 8.27 Mn |
| Mar 31, 2022 | 6.10 Mn |
| Dec 31, 2021 | 3.51 Mn |
| Sep 30, 2021 | 4.18 Mn |